Gornitzky represents biomedical company, Kadimastem, in USD 5.5 million IPO

June 10th, 2013 Back to all news

Gornitzky represented Kadimastem Ltd. (TASE: KDST) in its initial public offering of 3.1 million shares on the Tel Aviv Stock Exchange, for approximately USD 5.5 million. The underwriter of the offering was Rosario Capital Ltd.


Kadimastem is an Israeli biotechnology company focused on the industrial development and commercialization of human pluripotent stem cell-based products for the pharmaceutical and/or medical treatment of diabetes, neurodegenerative diseases and other indications.


Kadimastem Ltd. was represented by Sharon Werker-Sagy (Partner) and Etai Mashiah.